Anti-Mouse CD134 (Clone OX-86) – APC
Anti-Mouse CD134 (Clone OX-86) – APC
Product No.: C866
- -
- -
Clone OX-86 Target CD134 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names OX-40, TNFRSF4, ACT35 Isotype IgG1 κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day 2-8°C Additional Applications Reported In Literature ? FC IHC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone OX-86 reacts with murine CD134 (OX-40, TNFRSF4). Background CD134 functions as an important immune checkpoint, and its depletion in murine mouse models demonstrate that lack of CD134 expression leads to reduced CD4+ and CD8+ T cells1. When CD134 is bound by its corresponding ligand (OX-40L), an optimal T cell response is generated and plays a significant role in determining the amount of memory T-cells remaining after the immune response1. CD134 has also been found to play an important role in carcinogenesis, as treatment with activating in vivo antibodies against CD134 enhanced tumor growth, suggesting that CD134 is an important tumor suppressor, and its absence disrupts the immune response to tumors2,3. Antigen Distribution CD134 is expressed on activated CD4 and CD8 T cells, activated regulatory T cells, B cells, NKT cells, NK cells, and neutrophils. Research Area Immunology References & Citations1. Redmond WL, Ruby CE, Weinberg AD. Crit Rev Immunol. 29(3):187-201. 2019
2. Morris A, Vetto JT, Ramstad T, et. al. Breast Cancer Res Treat. 67: 71–80. 2001. 3. Weinberg AD, Rivera MM, Prell R, et. al. J Immunol. 164: 2160–9. 2000. 4. al-Shamkhani A, Birkeland ML, Puklavec M, et. al. Eur J Immunol. Aug;26(8):1695-9. 1996. 5. Higgins LM, McDonald SA, Whittle N, et. al. J Immunol. Jan 1;162(1):486-93. 1999. Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.